Not available
Quote | Astellas Pharma Inc (OTCMKTS:ALPMF)
Last: | $9.7868 |
---|---|
Change Percent: | 0.0% |
Open: | $9.7868 |
Close: | $9.7868 |
High: | $9.7868 |
Low: | $9.7868 |
Volume: | 100 |
Last Trade Date Time: | 07/01/2024 03:00:00 am |
News | Astellas Pharma Inc (OTCMKTS:ALPMF)
2024-06-01 17:52:36 ET More on Corbus Pharmaceuticals Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets Seeking Alpha’s Quant Rating on Corbus Pharmaceutical...
2024-05-31 13:04:02 ET More on Astellas Pharma Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript Astellas Pharma partners with YASKAWA for innovative cell therapy Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guida...
Message Board Posts | Astellas Pharma Inc (OTCMKTS:ALPMF)
Subject | By | Source | When |
---|---|---|---|
Astellas' Main Products: | scoobey-do | investorshub | 01/02/2021 7:43:55 PM |
Astellas Aspiration: | scoobey-do | investorshub | 01/02/2021 7:37:09 PM |
Astellas Innovation Management ($AIM) sounds like a partnership | SPORT19 | investorshub | 01/02/2021 5:25:04 PM |
One week ago ProtoKinetix $CEO Clarence Smith posted | SPORT19 | investorshub | 01/02/2021 5:24:42 PM |
Astellas has undergone a MASSIVE expansion of its | SPORT19 | investorshub | 01/02/2021 5:24:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...